Drug combo plus radiation for muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that has grown into the muscle layer of the bladder (called muscle-invasive bladder cancer).
- You are not able to have surgery to remove the bladder, or you choose not to have surgery.
- You are willing to have radiation therapy to the bladder.
- You have had a recent biopsy (TURBT) that shows live cancer cells in your bladder.
- Your cancer has not spread to distant parts of your body (like lungs, liver, or bones), and you have not had certain types of cancer treatment in the last 12 months.
- You have good kidney and liver function, and your blood counts are within certain ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It is for people with muscle-invasive bladder cancer who cannot take cisplatin chemotherapy.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat muscle-invasive bladder cancer. The goal is to see if this can help patients avoid having their bladder removed. It is for people who cannot or choose not to have surgery.
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.